Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3843 - Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): final results from an international trial (EORTC 05011)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Carlo Garufi


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


C. Garufi1, F. Levi2, A. Karaboué3, A. Torsello4, C. Focan5, P. Chollet6, P. INNOMINATO2

Author affiliations

  • 1 Medical Oncology, Ospedale Di Pescara, 65124 - Pescara/IT
  • 2 Medical School, University of Warwick, CV4 7AL - Coventry/GB
  • 3 Research & Therapeutic Innovation, AK-SCIENCE, 94400 - Vitry-sur-Seine/FR
  • 4 Oncology, San Giovanni Hospital, 00184 - Roma/IT
  • 5 Oncology, Centre Hospitalier Chrétien (CHC), 4000 - Liège/BE
  • 6 Oncology, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR


Abstract 3843


FOLFIRINOX is an effective yet toxic protocol against gastro-intestinal cancers. We report final updated global results from a randomised international trial aiming to identify the least toxic time of Irinotecan (I) combined with Oxaliplatin (O), 5-Fluorouracil (F) and Leucovorin (L).


199 MCC pts were randomised to receive chronomodulated I (180 mg/m2 over 6-h) on day 1 (d1) with peak delivery at 1:00, 5:00, 9:00, 13:00, 16:00 or 21:00, followed by 4-d fixed-time chronomodulated O (20 mg/m2/d) over 11.5 h, with peak delivery at 16:00, alternating with F (700 mg/m2/d) and L (300 mg/m2/d) over 11.5 h, with peak delivery at 4:00. ChronoIFLO was administered every 3rd week using an automatic programmable-in-time pump.


136 males (68%) and 63 females (32%) were registered at 18 centers. They had a median age of 61 years (range: 30-81), a WHO PS of 0 (73%), 1 (23%) or 2 (4%). ChronoIFLO4 was given as 1st (154 pts, 77%) or 2nd line (45 pts, 23%; 14 pts had previously received I and 20 pts, O). Pt features were similar in the 6 treatment groups. Median number of cycles was 6 (1-18), and mean relative dose intensities were 88% for I, 88% for O, 89% for F. Overall grade 3-4 toxicity occurred in 136/199 pts (68%) and 248/1158 cycles (21%). The most common severe toxicities were diarrhoea (43% of pts), nausea (19%), neutropenia (17%), fatigue (13%) and anorexia (11%). 1st line chronoIFLO achieved an objective response rate (ORR) of 61% [95% Confidence Limits: 53-69], a disease control rate (DCR) of 90% [85-95], a median progression-free survival (PFS) of 8.7 months (mo) [7.6-9.8], and a median overall survival (OS) of 19.5 mo [14.8-24.2]. Respective figures for 2nd line were: ORR, 39% [24-54]; DCR, 76% [63-89]; PFS, 7.4 mo [5.4-9.3]; OS, 16.6 mo [12.5-20.7].


Chronomodulated triplet showed favourable safety and activity profiles both as frontline or salvage treatment of MCC, in comparison to previous reports of conventional delivery. The therapeutic index of chronoIFLO could benefit from the personalisation of drug delivery patterns to match individual differences in internal clock phase.

Clinical trial identification

EORTC 05011

Legal entity responsible for the study

Warwick Medical School


Warwick Medical School


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.